Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | CLK3 | P49761 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.43 |
| ▸ | FLT1 | P17948 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535347 | 0.85 | CLK2 (0.61) | CLK2CLK3DYRK1ACHEK2ABL1 | |
| SCHEMBL3538630 | 0.84 | FGFR1 (0.55) | CLK2CLK3DYRK1ACHEK2ABL1 | |
| SCHEMBL3534764 | 0.84 | CLK2 (0.54) | CLK2CLK3DYRK1ACHEK2ABL1 | |
| SCHEMBL3540107 | 0.80 | FGFR1 (0.62) | CLK2CLK3DYRK1AABL1FGFR1 | |
| SCHEMBL3536317 | 0.79 | FGFR1 (0.63) | CLK2CLK3DYRK1ACHEK2ABL1 | |
| SCHEMBL3538634 | 0.77 | FGFR1 (0.49) | CLK2CLK3DYRK1ACHEK2ABL1 | |
| SCHEMBL3535537 | 0.77 | ABL1 (0.77) | ABL1FGFR1FLT1KDR | |
| SCHEMBL3534478 | 0.75 | CLK2 (0.48) | CLK2CLK3DYRK1AABL1FGFR1 | |
| SCHEMBL3532905 | 0.74 | FGFR1 (0.58) | CLK2CLK3DYRK1AABL1FGFR1 | |
| SCHEMBL3532735 | 0.73 | FGFR1 (0.51) | ABL1FGFR1FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CLK2 506/4885CLK3 877/4885DYRK1A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.